Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.24 CAD
Change Today 0.00 / 0.00%
Volume 49.3K
COT On Other Exchanges
Symbol
Exchange
OTC US
As of 2:28 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

critical outcome technologie (COT) Snapshot

Open
C$0.24
Previous Close
C$0.24
Day High
C$0.24
Day Low
C$0.24
52 Week High
06/17/14 - C$0.37
52 Week Low
05/16/14 - C$0.17
Market Cap
28.2M
Average Volume 10 Days
37.5K
EPS TTM
C$-0.04
Shares Outstanding
117.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CRITICAL OUTCOME TECHNOLOGIE (COT)

Related News

No related news articles were found.

critical outcome technologie (COT) Related Businessweek News

No Related Businessweek News Found

critical outcome technologie (COT) Details

Critical Outcome Technologies Inc., a bioinformatics company, is engaged in the discovery and development of small molecules. The company focuses on applying CHEMSAS, a proprietary computer based technology, which identifies, profiles, optimizes, selects, and validates commercially viable drug candidates at the discovery stage of preclinical drug development. It focuses on developing drug candidates for the treatment of various cancers, such as acute myelogenous leukemia, small cell lung, ovarian, endometrial, pancreatic, brain, breast, and colorectal cancers, as well as HIV, multiple sclerosis, Alzheimer’s disease, and methicillin-resistant staphylococcus aureus. Its lead oncology compound is COTI-2, a molecule in Phase I clinical trial. The company is also engaged in the development of Rosalind, which provides personalized oncology drug treatment recommendations to physicians and patients based on the genetic profile of each individual patient’s specific cancer. Critical Outcome Technologies Inc. is headquartered in London, Canada.

6 Employees
Last Reported Date: 07/24/14

critical outcome technologie (COT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$170.0K
Chief Financial Officer
Total Annual Compensation: C$130.0K
Compensation as of Fiscal Year 2014.

critical outcome technologie (COT) Key Developments

Critical Outcome Technologies Files Investigational New Drug Application with the FDA for COTI-2

Critical Outcome Technologies Inc. announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration s Center for Drug Evaluation and Research (FDA) for COTI-2, a potential breakthrough therapy intended for the treatment of women with gynecological cancers with p53 mutations. Advanced gynecological cancers have a particularly high prevalence rate (as high as 95%) of p53 mutations. The IND application is a complete description of the chemistry, non-clinical pharmacodynamics and pharmacokinetics, safety toxicology, manufacturing and other relevant information related to COTI-2 as a potential treatment for patients with p53 mutations. Subject to the FDA granting the IND application, the company intends to initiate a Phase 1 clinical trial of an oral formulation of COTI-2 in patients with gynecological cancers (cervical, endometrial and ovarian) at the University of Texas MD Anderson Cancer Center in Houston. Extensive preclinical studies have demonstrated COTI-2 s ability to restore mutant p53 function and thus induce cancer cell death in cancers with many common p53 mutations. In the upcoming clinical trial, the company intends to determine primarily the safety of COTI-2, as well as obtain some indications of efficacy, the maximum tolerated-dose and pharmacokinetics in treating gynecological cancers containing p53 mutations in patients who have failed the current first line therapies used in these types of cancers.

Critical Outcome Technologies Inc. Appoints Members to Scientific Advisory Board

Critical Outcome Technologies Inc. announced the formation of a Scientific Advisory Board to support the clinical development of its lead cancer drug candidate, COTI2. Appointed to the Scientific Advisory Board are Dr. Gordon Mills from the University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Douglas Levine from the Memorial SloanKettering Cancer Center in New York City, NY, Dr. David Parkinson from New Enterprise Associates in Menlo Park, CA, and Dr. Marshall Strome from the Center for Head and Neck Oncology at Mount SinaiRoosevelt Hospital in New York City, NY.

Critical Outcome Technologies Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended January 31, 2015

Critical Outcome Technologies Inc. announced unaudited earnings results for the third quarter and nine months ended January 31, 2015. The company incurred a net loss of $949,503, or $0.01 per share, for the quarter compared to a net loss of $671,386, or $0.01 per share, for the third quarter a year earlier. The increased loss for the quarter of $278,217 were attributable to increased expenses in all functional expense areas but primarily research and development and general and administration. For the nine months ended January 31, 2015, the company reported a loss of $2,866,502 or $0.03 per common share, compared to a loss of $1,769,658, or $0.02 per common share, for the same period last year. The increased loss for the year-to-date of $1,096,844 were attributable to increased expenses in all functional expense areas but primarily research and development and general and administration.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COT:CN C$0.24 CAD 0.00

COT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COT.
View Industry Companies
 

Industry Analysis

COT

Industry Average

Valuation COT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRITICAL OUTCOME TECHNOLOGIE, please visit www.criticaloutcome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.